ANNA-3 antibodies

Indication

Paraneoplastic neurological syndroms.

Method

Indirect immunofluorescence.

Answer

The result is given as negative or positive with a titer.

Interpretation

ANNA-3 is a rare paraneoplastic marker which have been detected in patients with small cell lung cancer (SCLC) but have also been found in lung adenocarcinoma and esophagus. Clinical symptoms are sensory-motor neuropathy with or without ataxia, cerebellar ataxia, brain stem encephalomyopathy with sensitivity disorders. The antibodies may be present along with other paraneoplastic markers such anti-Ri (Nova 1/ ANNA-2) and calcium channel antibodies (VGCC).

Read more about sampling

Packages and other tests

View other packages Paraneoplastic Syndromes and Limbic Encephalitis (560, 561 and 562). View other tests AMPA receptor 1 and 2 (GluR1 and GluR2) antibodies, Amphiphysin antibodies, CV2/CRMP5 antibodies, GABA B receptor antibodies, GAD antibodies, Glycine receptor (GlyR) antibodies, Hu antibodies, LGI-1 antibodies, Ma antibodies, NMDA receptor antibodies, Purkinje cell antibodies (PCA 2), Purkinje cell antibodies (Tr, Trotter antigen), Recoverin antibodies, Ri (Nova 1/ ANNA-2) antibodies, Ryanodine receptor antibodies, SOX1 antibodies, Titin antibodies, VGCC (voltage-gated calcium channel) antibodies, VGKC (voltage gated potassium channel) antibodies, Yo (PCA-1, Purkinje cells antigen 1) antibodies, Zic4 antibodies

20 years experience